187 related articles for article (PubMed ID: 27467961)
1. The clinical impact of ICOS signal in colorectal cancer patients.
Zhang Y; Luo Y; Qin SL; Mu YF; Qi Y; Yu MH; Zhong M
Oncoimmunology; 2016 May; 5(5):e1141857. PubMed ID: 27467961
[TBL] [Abstract][Full Text] [Related]
2. The Infiltration of ICOS
Zhang G; Xu Y; Zhou H
Pathol Oncol Res; 2020 Jan; 26(1):365-370. PubMed ID: 30361907
[TBL] [Abstract][Full Text] [Related]
3. The ICOSL Expression Predicts Better Prognosis for Nasopharyngeal Carcinoma via Enhancing Oncoimmunity.
Zhang G; Xu Y; Zhang S; Zhou H
Biomed Res Int; 2020; 2020():9756732. PubMed ID: 31998801
[TBL] [Abstract][Full Text] [Related]
4. The CD28 related molecule ICOS: T cell modulation in the presence and absence of B7.1/2 and regulational expression in multiple sclerosis.
Wiendl H; Neuhaus O; Mehling M; Wintterle S; Schreiner B; Mitsdoerffer M; Wienhold W; Weissert R; Wessels J; Hartung HP; Weller M; Tolosa E; Melms A
J Neuroimmunol; 2003 Jul; 140(1-2):177-87. PubMed ID: 12864987
[TBL] [Abstract][Full Text] [Related]
5. Inducible Costimulator Expressing T Cells Promote Parasitic Growth During Blood Stage
Jogdand GM; Sengupta S; Bhattacharya G; Singh SK; Barik PK; Devadas S
Front Immunol; 2018; 9():1041. PubMed ID: 29892278
[TBL] [Abstract][Full Text] [Related]
6. [High expression of ICOS on CD4
Chen X; Wang F; Cong X; Shen Q; Chen L
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2020 Dec; 36(12):1102-1108. PubMed ID: 33325362
[TBL] [Abstract][Full Text] [Related]
7. Unbalanced expression of membrane-bound and soluble inducible costimulator and programmed cell death 1 in patients with myasthenia gravis.
Yan X; Gu Y; Wang C; Sun S; Wang X; Tian J; Wang M; Ji X; Duan X; Gao H; Fang Q; Dong W; Zhang X; Xue Q
Clin Immunol; 2019 Oct; 207():68-78. PubMed ID: 31374257
[TBL] [Abstract][Full Text] [Related]
8. Expression and prognosis of inducible T-cell co-stimulator and its ligand in Chinese stage I-III lung adenocarcinoma patients.
Zhan XK; Liu XK; Zhang S; Chen H
Animal Model Exp Med; 2023 Oct; 6(5):464-473. PubMed ID: 37850501
[TBL] [Abstract][Full Text] [Related]
9. Muscle fibres and cultured muscle cells express the B7.1/2-related inducible co-stimulatory molecule, ICOSL: implications for the pathogenesis of inflammatory myopathies.
Wiendl H; Mitsdoerffer M; Schneider D; Melms A; Lochmuller H; Hohlfeld R; Weller M
Brain; 2003 May; 126(Pt 5):1026-35. PubMed ID: 12690043
[TBL] [Abstract][Full Text] [Related]
10. Mouse inducible costimulatory molecule (ICOS) expression is enhanced by CD28 costimulation and regulates differentiation of CD4+ T cells.
McAdam AJ; Chang TT; Lumelsky AE; Greenfield EA; Boussiotis VA; Duke-Cohan JS; Chernova T; Malenkovich N; Jabs C; Kuchroo VK; Ling V; Collins M; Sharpe AH; Freeman GJ
J Immunol; 2000 Nov; 165(9):5035-40. PubMed ID: 11046032
[TBL] [Abstract][Full Text] [Related]
11. The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy.
Fu T; He Q; Sharma P
Cancer Res; 2011 Aug; 71(16):5445-54. PubMed ID: 21708958
[TBL] [Abstract][Full Text] [Related]
12. ICOS/ICOSLG and PD-1 Co-Expression is Associated with the Progression of Colorectal Precancerous- Carcinoma Immune Microenvironment.
Zhang Y; Wang XL; Liu JJ; Qian ZY; Pan ZY; Song NP; Chen HY; Zhang W; Zhang X
J Inflamm Res; 2023; 16():977-992. PubMed ID: 36915615
[TBL] [Abstract][Full Text] [Related]
13. ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells.
Faget J; Bendriss-Vermare N; Gobert M; Durand I; Olive D; Biota C; Bachelot T; Treilleux I; Goddard-Leon S; Lavergne E; Chabaud S; Blay JY; Caux C; Ménétrier-Caux C
Cancer Res; 2012 Dec; 72(23):6130-41. PubMed ID: 23026134
[TBL] [Abstract][Full Text] [Related]
14. ICOS
Nagase H; Takeoka T; Urakawa S; Morimoto-Okazawa A; Kawashima A; Iwahori K; Takiguchi S; Nishikawa H; Sato E; Sakaguchi S; Mori M; Doki Y; Wada H
Int J Cancer; 2017 Feb; 140(3):686-695. PubMed ID: 27756099
[TBL] [Abstract][Full Text] [Related]
15. The B7 family revisited.
Greenwald RJ; Freeman GJ; Sharpe AH
Annu Rev Immunol; 2005; 23():515-48. PubMed ID: 15771580
[TBL] [Abstract][Full Text] [Related]
16. ICOS and CD28 reversely regulate IL-10 on re-activation of human effector T cells with mature dendritic cells.
Witsch EJ; Peiser M; Hutloff A; Büchner K; Dorner BG; Jonuleit H; Mages HW; Kroczek RA
Eur J Immunol; 2002 Sep; 32(9):2680-6. PubMed ID: 12207353
[TBL] [Abstract][Full Text] [Related]
17. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer.
Droeser RA; Hirt C; Viehl CT; Frey DM; Nebiker C; Huber X; Zlobec I; Eppenberger-Castori S; Tzankov A; Rosso R; Zuber M; Muraro MG; Amicarella F; Cremonesi E; Heberer M; Iezzi G; Lugli A; Terracciano L; Sconocchia G; Oertli D; Spagnoli GC; Tornillo L
Eur J Cancer; 2013 Jun; 49(9):2233-42. PubMed ID: 23478000
[TBL] [Abstract][Full Text] [Related]
18. A distinct role for ICOS-mediated co-stimulatory signaling in CD4+ and CD8+ T cell subsets.
Watanabe M; Hara Y; Tanabe K; Toma H; Abe R
Int Immunol; 2005 Mar; 17(3):269-78. PubMed ID: 15668466
[TBL] [Abstract][Full Text] [Related]
19. Comparable in vivo efficacy of CD28/B7, ICOS/GL50, and ICOS/GL50B costimulatory pathways in murine tumor models: IFNgamma-dependent enhancement of CTL priming, effector functions, and tumor specific memory CTL.
Zuberek K; Ling V; Wu P; Ma HL; Leonard JP; Collins M; Dunussi-Joannopoulos K
Cell Immunol; 2003 Sep; 225(1):53-63. PubMed ID: 14643304
[TBL] [Abstract][Full Text] [Related]
20. Role of the B7RP-1/ICOS pathway in renal tubular epithelial antigen presentation to CD4+ Th1 and Th2 cells.
Wahl P; Wüthrich RP
Nephron Exp Nephrol; 2004; 98(1):e31-8. PubMed ID: 15361696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
